Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

ALEC
Alector, Inc. Common Stock
stock NASDAQ

Market Open
May 15, 2025 3:18:03 PM EDT
1.07USD0.000%(0.00)1,238,459
1.07Bid   1.08Ask   0.01Spread
Pre-market
May 12, 2025 8:32:30 AM EDT
1.18USD+10.280%(+0.11)0
After-hours
May 14, 2025 4:00:30 PM EDT
1.07USD0.000%(0.00)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 3, 2022
04:30PM EST  Alector Reports Inducement Grants as permitted by the Nasdaq   GlobeNewswire Inc
Dec 15, 2021
08:30AM EST  Alector Announces Appointment of Sara Kenkare-Mitra, Ph.D., as   GlobeNewswire Inc
Nov 12, 2021
01:51PM EST  Alector Presents Encouraging New AL001 Data From The Symptomatic FTD-GRN Cohort Of INFRONT-2 Phase 2 Open-label Clinical Study   Benzinga
01:50PM EST  Alector Presents Encouraging New AL001 Data from the Symptomatic   GlobeNewswire Inc
07:20AM EST  Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Alector, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14   Benzinga
07:00AM EST  Preclinical Oncology Program Highlights Alectors Expertisein Harnessing Components of the Innate Immune System to Impact Disease   GlobeNewswire Inc
Nov 10, 2021
08:30AM EST  Alector, Inc.(Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, shared data from its AL003 and AL101 programs in poster presentations at the 14th Clinical Trials on Alzheimer's Disease (CTAD) conference being held November 9-12, 2021, virtually and in Boston.   GlobeNewswire Inc
Nov 9, 2021
11:42AM EST  The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data   Benzinga
Nov 8, 2021
04:05PM EST  Alector, Inc.(Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced thatArnon Rosenthal, Ph.D., Chief Executive Officer of Alector, will participate in a fireside chat at theStifel2021Virtual Healthcare ConferenceonMonday, November 15, 2021, at2:00 p.m. ET.   GlobeNewswire Inc
08:29AM EST  The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More   Benzinga
Nov 5, 2021
09:31AM EDT  Alector Q3 EPS $1.56 Up From $(0.67) YoY   Benzinga
Nov 3, 2021
07:06PM EDT  Alector To Present New Data From Multiple Pipeline Programs At 2021 CTAD Conference And SITC Annual Meeting   Benzinga
Sep 28, 2021
08:37AM EDT  Alector Appoints Elizabeth Garofalo To Board   RTTNews
08:30AM EDT  Alector, Inc.(Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the addition of Elizabeth (Betsy) A. Garofalo, M.D., to the Companys Board of Directors. Dr. Garofalo is a veteran biopharmaceutical executive with more than 25 years of experience in global clinical development and regulatory affairs, with a focus on neurology.   GlobeNewswire Inc
Sep 27, 2021
07:12AM EDT  William Blair Initiates Coverage On Alector with Outperform Rating   Benzinga
Sep 9, 2021
08:41AM EDT  Alector Announces First Participant Dosed In Phase 2 Study Evaluating AL001 In Amyotrophic Lateral Sclerosis   Benzinga
08:38AM EDT  Alector Doses First Patient In Phase 2 Study Evaluating AL001 In Amyotrophic Lateral Sclerosis   RTTNews
08:30AM EDT  Randomized, placebo-controlled Phase 2 trial will enroll patients with C9orf72-associated ALS   GlobeNewswire Inc
Sep 8, 2021
04:41PM EDT  Alector Says Appointed Linda Rubinstein As Co.'s Interim Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer   Benzinga
02:32PM EDT  Mid-Afternoon Market Update: Kadmon Surges Following Acquisition News; UiPath Shares Drop   Benzinga
02:29PM EDT  Mid-Day Market Update: Crude Oil Rises 1%; REV Group Shares Plummet   Benzinga
11:00AM EDT  Shares of clinical-stage biotechnology company Alector, Inc. (ALEC) are trading 17 percent down on Wednesday on news of its top management stepping down from their positions.   RTTNews
10:16AM EDT  Mid-Morning Market Update: Markets Mixed; Korn Ferry Reports Upbeat Q1 Results   Benzinga
07:32AM EDT  The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod   Benzinga
Sep 7, 2021
04:31PM EDT  Alector Announces Shehnaaz Suliman And Robert Paul Will Be Stepping Down From Their Respective Roles As President And Chief Operating Officer And Chief Medical Officer   Benzinga
04:30PM EDT  Planned Transitions Announced for Shehnaaz Suliman, M.D., MBA, MPhil, President and Chief Operating Officer and Robert Paul, M.D., Ph.D., Chief Medical Officer   GlobeNewswire Inc
Sep 2, 2021
07:00AM EDT  Alector, Inc.(Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming virtual investor conferences:   GlobeNewswire Inc
Aug 3, 2021
05:32PM EDT  Alector Q2 EPS $(0.69) Down From $(0.58) YoY, Sales $6.57M Up From $3.17M YoY   Benzinga
10:25AM EDT  Goldman Sachs Maintains Buy on Alector, Raises Price Target to $33   Benzinga
Jul 29, 2021
10:11AM EDT  Alector Presents 12-Month Results From INFRONT-2 Phase 2 Open Label Clinical Study Of AL001 For Treatment Of Symptomatic Frontotemporal Dementia Patients With Progranulin Mutation   Benzinga
08:18AM EDT  The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs   Benzinga
Jul 25, 2021
10:05AM EDT  The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More   Benzinga
Jul 21, 2021
04:38PM EDT  Alector To Present New Data From Frontotemporal Dementia And Alzheimer's Disease Programs At The 2021 Alzheimer's Association International Conference   Benzinga
04:35PM EDT  Oral Presentation to Highlight Data from the Ongoing Phase 2 Study of AL001 in FTD-GRNCompany to Host Analyst and Investor Conference Call on July 29 at 1:00 p.m. ET   GlobeNewswire Inc
Jul 16, 2021
08:21AM EDT  Morgan Stanley Maintains Overweight on Alector, Raises Price Target to $57   Benzinga
Jul 12, 2021
01:32PM EDT  EcoR1 Capital Reports In 13G Filing A 6% Stake In Alector   Benzinga
Jul 2, 2021
02:46PM EDT  Mid-Afternoon Market Update: Silver Rises 2%; Alector Shares Spike Higher   Benzinga
12:18PM EDT  Mid-Day Market Update: Dow Surges Over 100 Points; Arrowhead Pharmaceuticals Shares Plummet   Benzinga
10:28AM EDT  Mid-Morning Market Update: Markets Edge Higher; US Economy Adds 850,000 Jobs In June   Benzinga
08:26AM EDT  Alector Shares Jump On $2.2B Immuno-Neurology Development Pact With GSK   Benzinga
07:39AM EDT  Alector and GSK announce global collaboration in immuno-neurology   GlobeNewswire Inc
Jun 3, 2021
04:05PM EDT  Alector, Inc.(Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating officer of Alector, will participate in fireside chats at the following upcoming virtual investor conferences:   GlobeNewswire Inc
Jun 2, 2021
06:34AM EDT  CENTOGENE Initiates EFRONT Study To Identify Patients With Genetic Forms Of Frontotemporal Dementia; Study Being Conducted With Support From Alector   Benzinga
06:31AM EDT  CENTOGENE Initiates EFRONT Study to Identify Patients With Genetic   GlobeNewswire Inc
May 26, 2021
04:05PM EDT  Alector, Inc.(Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it will host a virtual key opinion leader event focused on frontotemporal dementia due to a progranulin gene mutation (FTD-GRN) onFriday, June 11, 2021 at10:30 a.m. ET.   GlobeNewswire Inc
May 5, 2021
04:48PM EDT  Alector, Inc. - Common Stock Q1 EPS $(0.66) Down From $(0.53) YoY, Sales $4.11M Down From $7.17M YoY   Benzinga
04:05PM EDT  -- Enrollment ongoing for AL001 INFRONT-3 Phase 3 trial in frontotemporal dementia with a progranulin mutation and for AL002 INVOKE-2 Phase 2 trial in early Alzheimers disease patients -- Three abstracts accepted for presentation at 2021 Alzheimers Association International Conference (AAIC), including updated data from ongoing AL001 open-label Phase 2 study in FTD-GRN   GlobeNewswire Inc
Apr 19, 2021
09:09AM EDT  Morgan Stanley Maintains Overweight on Alector, Raises Price Target to $33   Benzinga
Mar 25, 2021
04:05PM EDT  Alector, Inc.(Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating officer of Alector, will participate in a fireside chat at Stifels 3rd Annual CNS Day on Thursday, April 1, 2021, at 9:30 a.m. ET.   GlobeNewswire Inc
Mar 4, 2021
04:06PM EST  Alector, Inc.(Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating officer of Alector, will participate in a fireside chat at the Barclays Global Healthcare Conference on Thursday, March 11, 2021, at 2:25 p.m. ET.   GlobeNewswire Inc
Feb 25, 2021
04:36PM EST  Alector Q4 EPS $(0.66) Down From $(0.45) YoY, Sales $4.85M Down From $6.00M YoY   Benzinga
Jan 25, 2021
08:34AM EST  Alector Announces First Participant Dosed In Phase 2 Study Evaluating AL002 In Individuals With Early Alzheimer's Disease   Benzinga
08:30AM EST  -- AL002 is the first product candidate targeting TREM2 in Phase 2 clinical development -- Study will enroll early Alzheimers disease patients at up to 90 sites globally -- Alzheimers disease is a devastating neurological disease affecting nearly six million people in the U.S. and 35 million globally   GlobeNewswire Inc
Jan 20, 2021
04:15PM EST  -- Sabah Oney steps down from a role held since January 2018; joined Alector in October 2016 -- The departure will be effective February 1, 2021; will assist in transition until May 3, 2021   GlobeNewswire Inc
Jan 15, 2021
08:30AM EST  B of A Securities Reinstates Buy on Alector, Announces $35 Price Target   Benzinga
Jan 7, 2021
04:11PM EST  Alector Provides 2021 Corporate Portfolio Update   Benzinga
04:05PM EST  -- Clinical trials advancing for Phase 3 in frontotemporal dementia and Phase 2 in Alzheimers disease -- Updated data from ongoing AL001 Phase 2 study in frontotemporal dementia expected in 2021 -- The Company continues to maintain a strong balance sheet with more than $400 million in cash   GlobeNewswire Inc
Nov 11, 2020
04:05PM EST  Alector, Inc.(Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Sabah Oney, Ph.D., chief business officer of Alector, will participate in a fireside chat at the Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18, 2020, at 4:40 p.m. ET.   GlobeNewswire Inc
Nov 10, 2020
04:38PM EST  Alector Q3 EPS $(0.67) Down From $(0.47) YoY, Sales $5.90M Up From $2.70M YoY   Benzinga
04:05PM EST  -- Global Phase 3 INFRONT-3 trial evaluating AL001 for treatment of frontotemporal dementia due to a progranulin gene mutation (FTD-GRN) currently enrolling participants -- On track to initiate Phase 2 study for AL002 in Alzheimers disease in 2020 -- $461.7 million in cash and investments to support execution of clinical, research and operational goals   GlobeNewswire Inc
Nov 2, 2020
07:45AM EST  Prevail Therapeutics Announces Victory In Arbitration Brought By Alector Against Prevail's CEO; Says Arbitrator 'rejected all of Alector's principal claims against Dr. Abeliovich, including all claims alleging misappropriation or misuse of trade secrets'   Benzinga
07:44AM EST  -- Independent arbitrator finds in favor of Alector in confidential arbitration proceedings -- Dr. Abeliovich remains bound by contractual obligations related to the confidentiality of the companys intellectual property rights   GlobeNewswire Inc
Oct 22, 2020
04:10PM EDT  Alector To Highlight Early-Stage Cancer Programs At Upcoming Scientific Forums   Benzinga
04:05PM EDT  Alector, Inc.(Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that members of the Companys immuno-oncology team will provide an overview of the companys early-stage immuno-oncology research, specifically the AL008 development program, at two upcoming virtual scientific meetings.   GlobeNewswire Inc
07:52AM EDT  The Daily Biotech Pulse: FDA Vaccine Committee Meeting, Roche In $350M Deal for COVID-19 Treatment, Edwards Lifesciences Reports Q3 Beat   Benzinga
Oct 21, 2020
08:04AM EDT  The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings   Benzinga
Sep 3, 2020
04:05PM EDT  Alector, Inc.(Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that members of management will participate in fireside chats at the following upcoming virtual investor conferences:   GlobeNewswire Inc
Aug 11, 2020
04:22PM EDT  Alector Q2 EPS $(0.58) Down From $(0.36) YoY, Sales $3.17M Down From $6.92M YoY   Benzinga
04:05PM EDT  Alector Reports Second Quarter 2020 Financial Results and Provides   GlobeNewswire Inc
Aug 4, 2020
08:30AM EDT  Alector, Inc.(Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Sabah Oney, Ph.D., chief business officer, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference 2020 on Tuesday, August 11, 2020, at 11:00 a.m. ET.   GlobeNewswire Inc
Jul 29, 2020
02:38PM EDT  Mid-Afternoon Market Update: Dow Climbs 140 Points; Civeo Shares Jump Following Upbeat Q2 Results   Benzinga
12:00PM EDT  Mid-Day Market Update: Nasdaq Surges Over 100 Points; Eastman Kodak Shares Spike Higher   Benzinga
10:40AM EDT  Shares of Alector Inc. (ALEC) are losing nearly 18% on Wednesday morning. ALEC is currently trading at $17.44, down $3.90 or 18.28%, on the Nasdaq.   RTTNews
10:19AM EDT  Mid-Morning Market Update: Markets Open Higher; General Motors Posts Narrower-Than-Expected Loss   Benzinga
09:52AM EDT  Morning Market Stats in 5 Minutes   Benzinga
07:19AM EDT  Barclays Maintains Overweight on Alector, Lowers Price Target to $32   Benzinga
Jul 28, 2020
06:02PM EDT  UPDATE: Alector Says 15 Participants Evaluated, AL001 Obersved To Be Generally Safe, Well Tolerated, No Treatment-Related Serious Adverse Events, Data Showed Decrease In Plasma Levels From Baseline   Benzinga
06:01PM EDT  Alector Reports Prelim. Data From AL001 Phase 1b, 2 Open-Lable Long-Term Dosing Study Of People With Frontotemporal Dementia: Study Resulted In Sustained Restoration Of Plasma Progranulin Levels; Phase 3 Study Initiated In Jul.   Benzinga
Jul 27, 2020
07:57AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Mon., Jul. 27, 2020: FB, BA, ALEC, SCKT, GNCA   Benzinga
Jul 24, 2020
08:33AM EDT  Alector Reports Dosed First Patient In Pivotal Phase 3 INFRONT-3 Trial Evaluating AL001 In Patients With Frontotemporal Dementia   Benzinga
08:30AM EDT  -- Trial will enroll up to 180 symptomatic and pre-symptomatic participants with FTD-GRN gene mutation at multiple sites in the U.S., Europe and Australia -- There are currently no FDA-approved treatments for frontotemporal dementia   GlobeNewswire Inc
Jul 21, 2020
05:00PM EDT  Alector, Inc.(Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the company will highlight preliminary data from a Phase 2 open-label study evaluating AL001 in individuals with frontotemporal dementia at the upcoming 2020 Alzheimers Association International Conference being held virtually, July 27-31, 2020.   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC